阿托伐他汀钙对颈动脉粥样硬化斑块及C反应蛋白的影响

Effects of statins atorvastatin calcium on cerebral carotid atherosclerotic plaque and efficacy of C-reactive protein

目的：探讨阿托伐他汀钙对颈动脉粥样硬化斑块及CRP的影响。方法选择76例颈动脉粥样硬化斑块患者，采用数字表法随机分为观察组和对照组各38例，对照组仅给予常规治疗，观察组在对照组基础上给予阿托伐他汀钙治疗，比较治疗后两组颈动脉粥样硬化斑块的面积大小及血浆CRP变化情况。结果观察组治疗后斑块大小为（0．069±0．021）cm2，颈动脉内膜中层厚度（IMT）为（1．29±0.28）mm，均显著小于治疗前（t＝7．538、7．132，均P＜0．05），亦均明显小于对照组治疗后（t＝7．131、6．372，均P＜0．05）；观察组治疗后CRP为（3．54±1．92）mg/L，明显低于治疗前，治疗前后差异有统计学意义（t＝6.831，P＜0．05），且明显低于对照组治疗后（t＝7．125，P＜0．05）。结论对于颈动脉粥样硬化斑块的患者而言，应用阿托伐他汀钙治疗，不仅可有效缩小斑块面积，还可降低CRP，值得在临床中进一步应用。

Objective To investigate the clinical efficacy of statins atorvastatin calcium on cerebral carotid atherosclerotic plaques in patients and the effects on C-reactive protein .Methods 76 patients admitted to hospital with cerebral carotid atherosclerotic plaques in patients randomized manner using its divided into the observation group and control group of 38 patients in the control group not using statins , given only hospital conventional therapy , observed in the control group were given atorvastatin group based on calcium statin treatment ,post-treatment comparison groups the size of carotid atherosclerotic plaque and plasma C-reactive protein changes .Results After treatment , plaque size（0.069 ±0.021）cm2,IMT was （1.29 ±0.28）mm,significantly less than before treatment,after treatment difference was statistically significant （t=7.538,7.132,all P〈0.05）also significantly less than the control group ,the difference was statistically significant （t=7.131,6.372,all P〈0.05）;the observation group after treatment C-reactive protein（3.54 ±1.92 ） mg/L, significantly lower than before treatment , before and after treatment difference was statistically significant（t=6.831,P〈0.05）,and significantly lower than the control group ,the difference was also statistically significant（t=7.125,P〈0.05）.Conclusion For patients with cerebral carotid atherosclerotic plaque is concerned,the application of atorvastatin calcium treatment can not only effectively reduce plaque area , but also reduce C-reactive protein,and therefore worthy of further clinical application .